Conduit Pharmaceuticals Inc., a clinical stage life science company, has announced that it will transfer the listing of its common stock to The Nasdaq Capital Market. This decision follows the company's compliance with the necessary requirements for the move. The transfer of Conduit Pharmaceuticals' securities to The Nasdaq Capital Market is set to occur at the start of business on May 23, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.